203186-18-9

Upstream product

• 2354-91-8 (S)-2,2,2-trifluoro-(α-methylbenzyl)acetamide 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 56639-48-6 4-iodo-α(S)-methyl-benzylamine 
• 447460-40-4 C₁₆H₁₂ClF₄NO₃S 
• 1235874-31-3 N-[(S)-1-(4-cyano-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 
• 1218817-17-4 (S)-2,2,2-trifluoro-N-(1-(4-oct-1-ynylphenyl)ethyl)ethanamide 
• 306297-60-9 4-{4-[1-(S)-(4-iodophenyl)ethyl]-3(S)-methyl-1-piperazinyl}-1-(tert-butoxycarbonyl)piperidine 
• 726188-52-9 (S)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-2-methyl-4-piperidin-4-yl-piperazine 
• 306297-56-3 (S)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-6-methyl-piperazine-2,5-dione 
• 306297-58-5 1-[1(S)-4-iodophenylethyl]-2(S)-methylpiperazine 
• 203186-21-4 (R)-2-{(2-Chloro-acetyl)-[(S)-1-(4-iodo-phenyl)-ethyl]-amino}-propionic acid ethyl ester 
• 203186-23-6 (R)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-6-methyl-piperazine-2,5-dione 
• 203186-25-8 (R)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-2-methyl-piperazine 
• 203186-20-3 (R)-2-[(S)-1-(4-Iodo-phenyl)-ethylamino]-propionic acid ethyl ester 

Relevant academic research and scientific papers

Tuning the Circular Dichroism and Circular Polarized Luminescence Intensities of Chiral 2D Hybrid Organic–Inorganic Perovskites through Halogenation of the Organic Ions

Through the incorporation of various halogen-substituted chiral organic cations, the effects of chiral molecules on the chiroptical properties of hybrid organic–inorganic perovskites (HOIPs) are investigated. Among them, the HOIP having a Cl-substituted chiral cation exhibits the highest circular dichroism (CD) and circular polarized luminescence (CPL) intensities, indicating the existence of the largest rotatory strength, whereas the F-substituted HIOP shows the weakest intensities. The observed modulation can be correlated to the varied magnetic transition dipole of HOIPs, which is sensitive to the d-spacing between inorganic layers and the halogen–halogen interaction between organic cations and the inorganic sheets. These counteracting effects meet the optimal CD and CPL intensity with chlorine substitution, rendering the rotatory strength of HOIPs arranged in the order of (ClMBA)2PbI4>(BrMBA)2PbI4>(IMBA)2PbI4>(MBA)2PbI4>(FMBA)2PbI4.

Discovery of novel sphingosine kinase-1 inhibitors. Part 2

Building on our initial work, we have identified additional novel inhibitors of sphingosine kinase-1 (SK1). These new analogs address the shortcomings found in our previously reported compounds. Inhibitors 51 and 54 demonstrated oral bioavailability in a

Cannabinoid receptor ligands

The invention relates to compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmac

Synthesis and structure-Activity relationships of M2-Selective muscarinic receptor ligands in the 1-[4-(4-Arylsulfonyl)-phenylmethyl]-4-(4-piperidinyl)-piperazine family

The synthesis and muscarinic binding properties of compounds based on the 1-[4-(4-arylsulfonyl)phenylmethyl]-4-(1-aroyl-4-piperidinyl)-piperazine skeleton are described. For compounds, substituted with appropriately configured methyl groups at the benzylic center and at the piperazine 2-position, high levels of selective, M2 subtype affinity could be obtained, particularly when the terminal N-aroyl residue was ortho-substituted.

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten

Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm